07:00 , May 2, 2016 |  BioCentury  |  Finance

Private payday

AbbVie Inc. (NYSE:ABBV) is paying an eye-popping $5.8 billion up front and a potential $4 billion in milestones for privately held Stemcentrx Inc. , but the pharma thinks the price is worth it to obtain...
07:00 , Apr 11, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/8 cls Bind Therapeutics Inc. (NASDAQ:BIND) Cowen Eric Schmidt Downgrade Market perform (from outperform) -30% $1.57 Michael King Downgrade Market...
08:00 , Feb 8, 2016 |  BioCentury  |  Finance

Upsizing Qiming

With the close of its largest ever VC fund, Qiming Venture Partners expects to make larger investments and invest in more Chinese life sciences companies than it has in previous funds. On Feb. 1, Qiming...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Financial News

Bruker financial update

Bruker Corp. (NASDAQ:BRKR), Billerica, Mass.   Business: Supply/Service, Proteomics, Computational chemistry/biology   Date announced: 2015-11-13   Note: Bruker said its board authorized a new, $225 million share repurchase program over two years. Bruker, which closed...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

NK-ocking out cancer

Patrick Soon-Shiong is building what he hopes will be a suite of companies under the NantWorks LLC umbrella that together will help revolutionize cancer treatment. The latest is cancer immunotherapy company NantKwest Inc. (NASDAQ:NK), which...
07:00 , May 25, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/22 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) William Blair Katherine Xu Upgrade Outperform (from market perform) -4% $9.23 Xu also raised...
07:00 , May 4, 2015 |  BioCentury  |  Finance

Build to bye-bye

Versant Ventures last week saw its first build-to-buy company get taken out by Celgene Corp. (NASDAQ:CELG) and another enter into a partnership with Celgene, but the VC doesn't expect its recently closed fifth fund to...
07:00 , Apr 13, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/10 cls Bruker Corp. (NASDAQ:BRKR) Leerink Partners Dan Leonard Upgrade Outperform (from market perform) 7% $20.18 Leonard also raised his...
08:00 , Feb 16, 2015 |  BioCentury  |  Finance

Mann Bioinvest goes small

Mann Bioinvest has started raising capital for a new crossover fund to invest in undervalued small cap biotechs and to give the firm greater access to private company deals. The firm hopes to raise £50-£100...
08:00 , Dec 22, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/19 cls BioDelivery Sciences International Inc. (NASDAQ:BDSI) Roth Capital Partners Scott Henry Upgrade Buy (from neutral) 0% $13.82 Henry upgraded...